IMMUCELL CORP /DE/ ICCC
Nasdaq · XNAS · stock · In Vitro & In Vivo Diagnostic Substances
Chart by TradingView
7/9
Piotroski F — financial health
2.93
Altman Z″ — distress risk · safe
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $27.6M | -$1.0M | $11.4M | $1.2M | $27.1M |
| 2024 | $26.5M | -$2.2M | $7.9M | -$107,822 | $27.5M |
| 2023 | $17.5M | -$5.8M | $3.9M | -$6.6M | $25.0M |
| 2022 | $18.6M | -$2.5M | $7.6M | -$5.5M | $30.4M |
| 2021 | $19.2M | -$78,292 | $8.7M | -$1.7M | $32.6M |
| 2020 | $15.3M | -$1.0M | $6.9M | -$2.8M | $28.3M |
Why these scores methodology →
Piotroski F-score: 7/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: 2.93 (safe)
- Working capital / assets 0.305
- Retained earnings / assets -0.357
- EBIT / assets 0.039
- Equity / liabilities 1.748
Source: SEC EDGAR filings · CIK 0000811641 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.